바로가기메뉴

본문 바로가기 주메뉴 바로가기

logo

Mucopolysaccharidosis Type III: review and recent therapies under investigation

Journal of Interdisciplinary Genomics / Journal of Interdisciplinary Genomics, (E)2671-6771
2020, v.2 no.2, pp.20-25
https://doi.org/10.22742/JIG.2020.2.2.20
Jun Hwa Lee (Department of Pediatrics, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Korea)
  • Downloaded
  • Viewed

Abstract

Mucopolysaccharidosis type III (MPS III or Sanfilippo syndrome) is a multisystem lysosomal storage disease that is inherited in an autosomal recessive manner. It consists of four subtypes (MPS IIIA, B, C, and D), each characterized by the deficiency of different enzymes that catalyze the metabolism of the glycosaminoglycan heparan sulfate at the lysosomal level. The typical clinical manifestation of MPS III includes progressive central nervous system (CNS) degeneration with accompanying systemic manifestations. Disease onset is typically before the age of ten years and death usually occurs in the second or third decade due to neurological regression or respiratory tract infections. However, there is currently no treatment for CNS symptoms in patients with MPS III. Invasive and non-invasive techniques that allow drugs to pass through the blood brain barrier and reach the CNS are being tested and have proven effective. In addition, the application of genistein treatment as a substrate reduction therapy is in progress.

keywords
MPS III, Sanfilippo syndrome, blood brain barrier, Treatment, Genistein
Submission Date
2020-10-03
Revised Date
2020-10-13
Accepted Date
2020-10-31

Journal of Interdisciplinary Genomics